Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Pharma
J&J, Samsung Bioepis ink Stelara biosimilar settlement
Samsung Bioepis' biosimilar, which Sandoz has signed on to commercialize, can launch on Feb. 22, 2025, pending FDA approval.
Zoey Becker
Nov 30, 2023 4:48pm
FDA probes CAR-T therapies' 'serious risk' of secondary cancer
Nov 28, 2023 1:16pm
CEOs of J&J, Merck, BMS called to testify on drug prices
Nov 21, 2023 3:02pm
FDA calls for adcomm on BMS's Abecma in earlier treatment line
Nov 20, 2023 11:30am
2seventy suffers CAR-T commercialization pitfalls with Abecma
Nov 15, 2023 11:10am
J&J, Bayer's Xarelto proves its worth across PAD patients
Nov 14, 2023 11:33am
